Related Experiment Video
Updated: May 28, 2026
07:35
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Coenzyme Q10 deficiency in septic shock patients
Laurent Dupic1, Olivier Huet, Jacques Duranteau
1Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Département d'Anesthésie-Réanimation, EA 3509 Université Paris Sud XI, France F-94275, Le Kremlin-Bicêtre, France.
Critical Care (London, England)
|October 21, 2011
Summary
Septic shock may cause a deficiency in coenzyme Q10 (CoQ10), an important molecule for energy production. Further research is needed to confirm this finding and explore CoQ10 as a potential treatment for septic shock patients.
Area of Science:
- Biochemistry
- Critical Care Medicine
- Mitochondrial Biology
Background:
- Septic shock is a life-threatening condition characterized by circulatory, cellular, and metabolic abnormalities.
- Oxidative stress and mitochondrial dysfunction are implicated in the pathophysiology of septic shock.
Discussion:
- This study investigates the potential role of coenzyme Q10 (CoQ10) deficiency in patients experiencing septic shock.
- CoQ10 is a vital component of the mitochondrial electron transport chain, crucial for cellular energy production.
Key Insights:
- The research suggests a possible link between septic shock and depleted levels of coenzyme Q10.
- This potential deficiency may contribute to the observed mitochondrial dysfunction in septic shock patients.
Outlook:
- Larger prospective observational studies are necessary to validate the hypothesis of CoQ10 depletion in septic shock.
- Confirming CoQ10 deficiency could pave the way for investigating CoQ10 as a novel therapeutic strategy for septic shock.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:26Acute Coronary Syndrome V: Nursing Management
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...